Claudia Soares | Lead Scientist Drug Substance
CDR-Life

Festival of Biologics Day 1 @ 16:50

Streamlining M-gager Development: From CHO Pool to Process Lock

CDR-Life is transforming the treatment of cancer and autoimmune diseases with its proprietary M-gager® T cell engager format, enabling highly selective targeting of both conventional and previously difficult-to-address antigens. Our integrated, end-to-end development approach accelerates the creation of promising drugs against challenging targets. This is achieved through synergistic, multidisciplinary collaboration across the discovery, pharmacology, preclinical, and technical development functions at CDR-Life. To streamline process development toward clinical manufacturing, our CMC team leverages a strong partnership with a cell line developer for synchronized CHO cell line and upstream process development. Our established M-gager® platform process facilitates efficient process development starting with stable pools, enabling the production of representative material for animal and preclinical safety studies at an early stage. We reduce risks and ensure smooth, timely tech transfers by aligning clone selection and process optimization with both the cell line provider and the CDMO. Our integrated approach supports rapid development and scalable manufacturing, positioning CDR-Life to deliver transformative immunotherapies to patients with high unmet needs

Claudia Soares, Lead Scientist Drug Substance, CDR-Life

×

Claudia Soares / Streamlining M-gager Development: From CHO Pool to Process Lock

Claudia Soares, Lead Scientist Drug Substance,
CDR-Life

Cláudia is a trained Pharmacist and obtained her MSc from the University of Coimbra, in Portugal. She started her career at a CDMO with a focus on cell line and cell culture development. Cláudia joined the USP team at CDR-Life over two years ago and is now Lead Scientist in the Drug Substance...

CloseMore